Crossmark

Immune-mediated cholangitis: is it always nivolumab’s fault?

Crossref DOI link: https://doi.org/10.1007/s00262-018-2159-3

Published Online: 2018-04-05

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gelsomino, Francesco

Vitale, Giovanni

Ardizzoni, Andrea
License Information

Text and Data Mining valid from 2018-04-05
More Information

Article History

Received: 3 February 2018

Accepted: 2 April 2018

First Online: 5 April 2018

Compliance with ethical standards

:

: All authors declare that they have no conflict of interest.